These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6590115)

  • 1. Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide.
    Letendre L; Ludwig J; Perrault J; Smithson WA; Kovach JS
    Cancer; 1984 Oct; 54(7):1256-9. PubMed ID: 6590115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of indicine N-oxide in refractory acute leukemia.
    Letendre L; Smithson WA; Gilchrist GS; Burgert EO; Hoagland CH; Ames MM; Powis G; Kovach JS
    Cancer; 1981 Feb; 47(3):437-41. PubMed ID: 7013959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia.
    Winton EF; McCue PA
    Cancer Treat Rep; 1986 Jul; 70(7):933-4. PubMed ID: 3459576
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of indicine N-oxide in relapsed acute leukemia of childhood. A report from the Childrens Cancer Study Group.
    Miser JS; Smithson WA; Krivit W; Hughes CH; Davis D; Krailo MD; Hammond GD
    Am J Clin Oncol; 1992 Apr; 15(2):135-40. PubMed ID: 1553901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study.
    Whitehead VM; Bernstein ML; Vega R; Vats T; Dyment P; Vietti TJ; Krischer J
    Cancer Chemother Pharmacol; 1990; 26(5):377-9. PubMed ID: 2208580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic failure secondary to indicine N-oxide toxicity. A Pediatric Oncology Group Study.
    Cook BA; Sinnhuber JR; Thomas PJ; Olson TA; Silverman TA; Jones R; Whitehead VM; Ruymann FB
    Cancer; 1983 Jul; 52(1):61-3. PubMed ID: 6573942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indicine-N-oxide: a new antitumor agent.
    Poster DS; Bruno S; Penta J; Macdonald JS
    Cancer Treat Rep; 1981; 65(1-2):53-6. PubMed ID: 6939484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of Indicine-N-Oxide on two dose schedules.
    Taylor S; Belt RJ; Haas CD; Hoogstraten B
    Cancer; 1983 Jun; 51(11):1988-91. PubMed ID: 6839292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indicine N-oxide: clinical use of a pyrrolizidine alkaloid.
    King SA; Suffness M; Leyland-Jones B; Hoth DF; O'Dwyer PJ
    Cancer Treat Rep; 1987 May; 71(5):517-23. PubMed ID: 3552221
    [No Abstract]   [Full Text] [Related]  

  • 10. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Moore JO; Olsen GA
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of indicine N-oxide in relapsed pediatric solid tumors. A report from the Childrens Cancer Study Group.
    Miser JS; Smithson WA; Krivit W; Hughes C; Davis D; Krailo M; Hammond D
    Invest New Drugs; 1991 Nov; 9(4):339-42. PubMed ID: 1804809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.
    Powis G; Ames MM; Kovach JS
    Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):559-69. PubMed ID: 451340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Meyer P; Ho AD; Ehninger G; Mjaaland I; Heidemann E; Seither E
    Invest New Drugs; 1985; 3(2):203-6. PubMed ID: 3860490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute nonlymphocytic leukemia with neocarzinostatin.
    Griffin TW; Lister TA; Rybak ME; Rosenthal DS; Canellos GP; Woodruff R; Oliver KT
    Cancer Treat Rep; 1979; 63(11-12):1853-6. PubMed ID: 160835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.